Research progress and application of animal models for drug development in multiple sclerosis
- Author:
Jia-Ying ZHAO
1
;
Yan-Jia SHEN
1
;
Ran YANG
1
;
Miao CHEN
1
;
Li LI
1
;
Guan-Hua DU
1
Author Information
- Publication Type:Journal Article
- Keywords: demye¬lination model; drug discovery; experimental autoimmune encephalomyelitis; MS animal models; MS clinical phenotype; multiple sclerosis
- From: Chinese Pharmacological Bulletin 2022;38(6):801-806
- CountryChina
- Language:Chinese
- Abstract: Multiple sclerosis ( MS) is an immune-mediated chro¬nic inflammatory disease of the central nervous system (CNS) , which is regulated by multiple pathophysiological mechanisms.There are four clinical phenotypes of MS, including relapsing-re- mitting MS ( RRMS) , primary progressive MS ( PPMS) , sec- ondary-pmgressive MS ( SPMS) , and progressive relapsing MS ( PRMS) , among which RRMS is the main type.'Hie pathogen¬esis of MS is not clear and it could not he cured, so long-term drug treatment is needed for the MS patients.Nowadays, animal models play an important role in the preclinical research of MS drugs.'Hie MS animal models are mainly divided into experi¬mental autoimmune encephalomyelitis (EAE) model, toxin in¬ duced demyelination model, and vims induced demyelination model, among which EAE model is most widely used.'Hie three types of MS animal models demonstrate specific characteristics due to the different induction methods and animal species, and they correspond to specific clinical types of MS.According to the different clinical types of MS, the use of appropriate animal models for drug research and development will help us develop more targeted and potential therapeutic dnrgs, making it possible to cure MS.
